METTL14 and breast cancer: Zhang et al. (Zhang et al., 2021a) found that Isorhapontigenin (ISO) could upregulate the expression of METTL14 by activating the transcription factor FOXO3a, and then downregulating the epithelial-to-mesenchymal transition (EMT) marker vimentin in an m6A-dependant manner, which in turn inhibits EMT and invasion in BC.